Press Releases 2025 2024 2023 2022 2021 2020 2019 all November 9, 2020 Dyne Therapeutics to Present at Upcoming Investor Conferences November 5, 2020 Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights September 21, 2020 Dyne Therapeutics Announces Closing of Initial Public Offering September 16, 2020 Dyne Therapeutics Announces Pricing of Initial Public Offering August 10, 2020 Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases August 3, 2020 Dyne Therapeutics Appoints Susanna High as Chief Operating Officer July 20, 2020 Dyne Therapeutics Announces Appointment of Leading DMD Expert Francesco Muntoni to Scientific Advisory Board June 11, 2020 Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property May 19, 2020 Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board May 12, 2020 Dyne Therapeutics Demonstrates FORCE TM Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy May 11, 2020 Dyne Therapeutics Announces Appointment of Debra Feldman as Vice President, Head of Regulatory April 23, 2020 Dyne Therapeutics Appoints David Lubner to Board of Directors March 31, 2020 Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD February 6, 2020 Dyne Therapeutics Expands Leadership Team with Key Hires January 13, 2020 Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy
